AbbVie Inc
ABBV#105 of 134 by buybacksNYSE · Healthcare · Drug Manufacturers - General · USA
abbvie.comBuybacks · FY2025$980Mlatest fiscal year
Buyback yield0.2%repurchases ÷ market cap
Dividends · FY2025$11.7Bdividend yield 2.4%
Shareholder yield2.6%buybacks + dividends ÷ market cap
Shares outstanding · 5 yr−0.4%1.77B shares (2026)
Buybacks ÷ free cash flow6%payout incl. dividends 71%
Fiscal-year detail
From the cash-flow statement as reported, in USD. Negative repurchases mean net share issuance.
| Fiscal year | Repurchases | Dividends | Free cash flow |
|---|---|---|---|
| FY2025Dec 2025 | $980M | $11.7B | $17.8B |
| FY2024Dec 2024 | $1.71B | $11.0B | $17.8B |
| FY2023Dec 2023 | $1.97B | $10.5B | $22.1B |
| FY2022Dec 2022 | $1.49B | $10.0B | $24.2B |
| FY2021Dec 2021 | $934M | $9.26B | $22.0B |
| FY2020Dec 2020 | $978M | $7.72B | $16.8B |
| FY2019Dec 2019 | $629M | $6.37B | $12.8B |
Repurchases in FY2025 were −42.6% versus the prior year.
About AbbVie Inc
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables,…
- Market cap
- $489B
- P/E (trailing)
- 78.1×
- Fiscal year end
- December
- ISIN
- US00287Y1091
- Reporting currency
- USD
- Data updated
- Oct 10, 2026